Replies to post #199792 on Avid Bioservices Inc (CDMO)

[corporalagarn]

Classic. You obviously have no idea how this puzzle thing works.

[biopharm]

you have touted,IMO,yes touted Soon-Shiong as the brilliant one who would/should/must(?) know about PPHM/Bavi and why not throw his backing towards us as he is right on the cutting edge of our knowledge all things Bavi. Now that it APPEARS he has possibly moved on to someone else you are going to bring up Sonia Perez ad nauseum because of some more puzzle pieces?

PR, just because one party runs parallel studies or collaborates with more than one does not mean they intend to drop all others. Hell, if this was the way of thinking, why has not Big Pharma bought out "ALL" worthy pipelines at the ealier stage instead of waiting when it costs them Billions of dollars?

You said it yourself above in red, it "APPEARS" Soon-Shiong has moved on and that is like saying Cisplatin worked and will corner the market lol

There are many chemos, there are many more drugs and what I exactly said was:

"We may be able to but either way, if he is out.... and Soon-Shiong moving faster than any BP or CALICO... this effort by Soon-Shiong should help speed others along as well. Good for Peregrine either way, because this is not a time where anyone can just sit around and wait... "

In other words, everyone must have an IO - Immuno-Oncology tapped pipeline and Peregrine has one ready to go with Sunrise moving along.

PR, you surprise me as you could possibly think that I was moving from a Soon-Shiong to a Sonia Perez to partner with lol

Soon-Shiong is worth north of $10Billion

A Roche can part with much more than $10Billion

CALICO can put out much more than $10Billion and that has always been my #1 choice, so please don't try to say that Soon-Shiong was my #1 choice. What Soon-Shiong will do though... is make Peregrines deal surface faster than expected.

On final note...I will say this, Sonia Perez comes closer to showing me that they are working with PS Targeting antibodies with this statement:

"For instance, the center is developing a therapy that targets macromolecules solely on the outer membranes of tumor cells to deliver drugs as an alternative to traditional chemotherapy or radiotherapy, both of which target normal cells in addition to tumorous cells, and create serious side effects. "

http://investorshub.advfn.com/boards/replies.aspx?msg=109077155